Protein Disulfide Isomerase: Function, Roles & Health

Protein disulfide isomerase, usually called PDI, is an enzyme that lives inside cells and helps newly made proteins fold into their correct three-dimensional shapes. It does this primarily by forming, breaking, and rearranging the chemical bridges known as disulfide bonds, which act like molecular staples holding a protein’s structure together. But PDI turns out to do far more than fold proteins. Researchers have found it on cell surfaces helping blood clots form, at the gates where viruses enter cells, and tangled up in diseases from heart attacks to neurodegeneration, making it one of the more surprisingly versatile molecules in human biology.

What PDI Actually Does Inside the Cell

Most proteins that your cells secrete or display on their surfaces pass through a cellular compartment called the endoplasmic reticulum, or ER. There, they need to fold into precise shapes to work properly. Many of these proteins require disulfide bonds to hold parts of their structure together. PDI is the main enzyme responsible for catalyzing these bonds. It can introduce new disulfide bonds into unfolded proteins (oxidation), break incorrect ones (reduction), and shuffle misplaced ones into the right positions (isomerization).¹ That trio of activities is critical because a single misplaced disulfide bond can render a protein useless or, worse, cause it to clump into toxic aggregates.

PDI does not work alone. After it donates disulfide bonds to a substrate protein, PDI itself ends up in a reduced state and needs to be recharged. An enzyme called Ero1 handles this step, accepting electrons from PDI and passing them along to oxygen.² The result is a relay: Ero1 oxidizes PDI, PDI oxidizes the target protein, and the electrons ultimately flow to molecular oxygen.³ Without this cycle, disulfide bond formation stalls and misfolded proteins pile up.

More Than an Enzyme

PDI also moonlights as a molecular chaperone, meaning it can physically bind to unfolded or partially folded proteins and prevent them from sticking to each other in harmful aggregates. This chaperone ability is separate from its disulfide-shuffling chemistry. Research has shown that PDI’s chaperone function is driven mainly by a region of the protein called the b’ domain, and it works even on proteins that do not contain any disulfide bonds at all.⁴ PDI is also a required subunit of two other enzymes. One is prolyl 4-hydroxylase, which is essential for building collagen, the structural protein in skin, tendons, and bone. The other is the microsomal triglyceride transfer protein, which packages fats for transport out of the liver and intestine. Without PDI, neither of those enzymes can assemble or function properly.

A Big Family With Specialized Members

PDI is not a single protein but the founding member of a large gene family. In humans, the PDI family contains 21 known members, each varying in size, tissue expression, and which proteins they prefer to work on.⁵ One well-studied relative, ERp57, shares the same general architecture as PDI but is steered toward different substrates. ERp57 partners with a pair of quality-control lectins called calnexin and calreticulin, and its noncatalytic b’ domain is what determines that preference.⁶ Another family member, PDIA6, plays a role in heart protection and insulin processing, discussed further below. The family is not unique to mammals. Yeast have five PDI-family members, land plants have about ten, and some algae harbor additional classes not found in other organisms.⁷ The proliferation of so many relatives likely reflects the fact that different cell types and different substrate proteins have distinct folding demands.

PDI on the Cell Surface and in Blood Clots

For decades, PDI was assumed to stay inside the ER. That assumption turned out to be wrong. Certain cell types, particularly platelets, release PDI onto their outer surface and even secrete it into the blood. On the platelet surface, PDI rearranges disulfide bonds on receptors that control clotting and inflammation. Blocking PDI on platelets with antibodies inhibits integrin-mediated aggregation, adhesion, and granule secretion, essentially stopping many of the steps needed for a blood clot to form.⁸

Work in mouse models has sharpened the picture further. Platelet PDI was found to directly bind to and reduce specific disulfide bonds on a surface receptor called GPIbα. That reduction is needed for GPIbα to grab its binding partners, and without it, platelet-neutrophil interactions and the kind of vascular blockages seen in sickle cell disease and stroke are significantly reduced.⁹ This makes extracellular PDI an appealing drug target for preventing harmful clots without completely shutting down the clotting system.

Helping Viruses Get In

If PDI can reshape receptors on cell surfaces, then viruses can hijack that activity. And several do. HIV-1 is the best-studied example. The virus’s envelope protein, gp120, needs to undergo a conformational change after binding its receptor to expose the fusion machinery that lets the virus enter the cell. PDI on the host cell surface catalyzes the disulfide rearrangements in gp120 that make this conformational change possible. Agents that block PDI effectively prevent the virus from fusing with and entering host T cells, and adding PDI back reverses that block.¹⁰

HIV is not the only virus that exploits this trick. Newcastle disease virus, which infects birds and is a concern in poultry farming, also depends on cell-surface thiol-disulfide exchange for its fusion protein to become active. Inhibitors of PDI-family enzymes block both cell-to-cell fusion and viral entry in that system as well, without killing the host cells.¹¹ The pattern suggests that disulfide shuffling at the cell surface may be a common vulnerability for enveloped viruses, and blocking it could in principle be a broad antiviral strategy.

PDI in Neurodegenerative Disease

Cells that are struggling with misfolded proteins ramp up PDI production as part of a stress response called the unfolded protein response, or UPR.¹² In theory, more PDI should help clear the backlog of misfolded proteins. But in Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS), something goes wrong. A chemical modification called S-nitrosylation attaches a nitric oxide group to the active-site cysteines on PDI, effectively shutting the enzyme down.¹³

In ALS specifically, researchers detected increased levels of S-nitrosylated PDI in spinal cord tissue from both human patients with sporadic ALS and mice carrying ALS-linked mutations in the SOD1 gene.¹⁴ Disease progression in the mouse model was accompanied by rising levels of the enzyme iNOS, which produces nitric oxide, followed by a dose-dependent increase in S-nitrosylated PDI.¹⁵ So the cell tries to protect itself by making more PDI, but nitric oxide disarms it. The result is a vicious cycle: misfolded proteins accumulate, more stress signals are generated, more nitric oxide is produced, and more PDI is inactivated.

Heart Protection

The heart is another organ where PDI’s protective instincts show up clearly. During a heart attack, the tissue around the damaged zone is at risk of dying, and the cells in that border region upregulate PDI as a survival mechanism. One study found that PDI levels were about three-fold higher in the viable tissue bordering the infarct than in healthy heart muscle, and higher PDI expression correlated with lower rates of cell death and less heart failure. When researchers forced PDI expression in mouse hearts using gene transfer, infarct size shrank roughly two-and-a-half-fold and cell death in the border zone fell significantly.¹⁶

The family member PDIA6 has a complementary role. Lab experiments showed that overexpressing PDIA6 in heart muscle cells reduced death during simulated ischemia, and this protection depended specifically on the enzyme’s ability to catalyze disulfide bond rearrangement. Knocking PDIA6 down, conversely, increased cell death even under normal conditions.¹⁷ On the diagnostic side, patients who had experienced cardiovascular events like heart attacks, unstable angina, or strokes showed lower levels of circulating PDI in their blood compared to healthy individuals, hinting that blood PDI levels might someday serve as a marker of cardiovascular risk.¹⁸

PDI and the ER Stress Safety Valve

When misfolded proteins build up in the ER faster than they can be fixed, cells activate the UPR to either solve the problem or, if the damage is too severe, trigger cell death. PDI intersects with this safety valve in a surprisingly direct way. When phosphorylated by a kinase called Fam20C, PDI gains the ability to bind IRE1α, one of the main sensors that switches on the UPR. Phosphorylated PDI tamps down excessive IRE1α activity, effectively preventing the stress response from overshooting and killing the cell. Mice engineered to lack this phosphorylation site on PDI showed exaggerated IRE1α activation and worse liver damage when subjected to acute ER stress.¹⁹ In other words, PDI is not just a worker bee folding proteins; it is also part of the control system that decides how loudly the alarm bells ring.

The Insulin Connection

Insulin begins life as a precursor called proinsulin, which needs to form three precise disulfide bonds in the ER before it can be processed and secreted. PDI has long been assumed to help with this folding, but the reality turned out to be more nuanced. When researchers knocked PDI down in pancreatic beta cells, proinsulin’s disulfide bonds still formed correctly and, surprisingly, proinsulin actually exited the ER faster and insulin secretion went up. The data suggested that PDI acts as a brake on proinsulin export, possibly through an “unfoldase” activity that keeps some proinsulin molecules cycling back for additional quality checks.²⁰

PDI family members also handle damage control. When a proinsulin molecule is terminally misfolded, as happens with the Akita mutation that causes neonatal diabetes, PDI reduces the misfolded protein’s disulfide bonds to prime it for disposal through the cell’s waste-removal pathway.²¹ More recent work has uncovered an additional layer. PDIA6 was found to form droplet-like condensates in the ER in response to calcium signals, and these condensates actively recruit proinsulin, accelerating its oxidative folding while preventing it from aggregating. This process appears essential for efficient insulin production.²² The emerging picture is that PDI family members collectively tune insulin output: one acts as a quality gatekeeper, another clears failures, and a third speeds successful folding through specialized compartments.

PDI as a Drug Target

Because PDI is involved in so many disease processes, the pharmaceutical interest is obvious. Several research groups have developed small-molecule PDI inhibitors with different strategies and goals.

In cancer, PDI activity appears essential for the survival of certain tumor cells. An irreversible PDI inhibitor called PACMA 31, designed to lock onto PDI’s active-site cysteines, significantly suppressed ovarian tumor growth in mice without causing toxicity to normal tissues.²³ A separate compound class (called T8) was found to sensitize cancer cells to the chemotherapy drug etoposide at doses that were not themselves toxic, working through reversible PDI inhibition.²⁴ Allosteric inhibitors, which bind PDI outside its active site, have also shown promise against glioblastoma cells, where they induce ER stress and interfere with DNA repair.

For HIV, the natural compound juniferdin was identified as a potent and specific PDI inhibitor, blocking the enzyme’s ability to reduce disulfide bonds in the viral envelope protein gp120. Juniferdin and its optimized derivatives inhibited PDI at concentrations in the low nanomolar range while leaving related family members largely unaffected.²⁵ Although none of these compounds have yet reached routine clinical use, they establish that it is possible to hit PDI selectively. The challenge going forward is precision. Because PDI is everywhere and does so many things, a drug that shuts it down in the wrong tissue or at the wrong time could easily cause harm.

PDI and Metal Handling

An often-overlooked aspect of PDI is its ability to bind metals, especially copper. Under experimental conditions, freshly reduced PDI can bind up to four copper ions and convert them from one oxidation state to another. In the presence of a reducing agent, the number of copper ions bound increases to about ten per molecule, and the copper shifts to a more protected environment within the protein. Copper-loaded PDI forms tetramers rather than staying in its usual monomeric state, suggesting that metal binding triggers a structural rearrangement.²⁶ Whether this plays a physiological role is still an open question, but it is intriguing in the context of diseases like Wilson disease and certain neurodegenerative conditions where copper metabolism goes awry. If PDI participates in buffering copper levels in the ER, losing that capacity through S-nitrosylation or other damage could add another layer to the toxicity seen in those diseases.